Table 1.

Participant demographic characteristics (full analysis set) per treatment group for participants in the one-dose cohort

		Low-dose plus AF03 group (n=34)	Low-dose plus AS03 group (n=34)	High-dose plus AF03 group (n=34)	High-dose plus AS03 group (n=34)	Placebo group (n=34)
Aged 18–49 years
Sex
	Female	14/24 (58%)	9/24 (38%)	13/24 (54%)	14/24 (58%)	12/24 (50%)
	Male	10/24 (42%)	15/24 (62%)	11/24 (46%)	10/24 (42%)	12/24 (50%)
Age, years		36·0 (10·0)	35·4 (8·66)	32·0 (9·69)	29·7 (8·88)	31·1 (8·45)
Race or ethnicity
	White	20/24 (83%)	21/24 (88%)	22/24 (92%)	16/24 (67%)	20/24 (83%)
	Asian	1/24 (4%)	2/24 (8%)	1/24 (4%)	4/24 (17%)	1/24 (4%)
	American Indian or Alaska Native	0	0	0	1/24 (4%)	1/24 (4%)
	Black or African American	1/24 (4%)	0	0	1/24 (4%)	0
	Multiple	0/24	1/24 (4%)	1/24 (4%)	0	1/24 (4%)
	Not reported or unknown	2/24 (8%)	0/24	0/24	2/24 (8%)	1/24 (4%)
	Hispanic or Latino	6/24 (25%)	2/24 (8%)*	3/24 (13%)	3/24 (13%)	7/24 (29%)
Aged 50 years or older
Sex
	Female	8/10 (80%)	6/10 (60%)	4/10 (40%)	7/10 (70%)	6/10 (60%)
	Male	2/10 (20%)	4/10 (40%)	6/10 (60%)	3/10 (30%)	4/10 (40%)
Age, years		59·3 (7·07)	57·3 (5·70)	58·5 (9·29)	61·3 (10·1)	60·1 (7·74)
Race or ethnicity
	White	9/10 (90%)	7/10 (70%)	8/10 (80%)	9/10 (90%)	10/10 (100%)
	Asian	1/10 (10%)	1/10 (10%)	0	1/10 (10%)	0
	Black or African American	0	1/10 (10%)	0	0	0
	American Indian or Alaska Native	0	0	0	0	0
	Native Hawaiian or Other Pacific Islander	0	1/10 (10%)	0	0	0
	Multiple	0	0	1/10 (10%)	0	0
	Not reported or unknown	0	0	1/10 (10%)	0	0

Data are n/N (%) or mean (SD).

^*Hispanic or Latino ethnicity was not reported for one participant in the high-dose plus AF03 group, in the 18–49 years stratum.